Jiahui Zhang1, Yongye Chen1, Yanyan Zhang2, Enlong Zhang1, Hon J Yu3, Huishu Yuan1, Yang Zhang3, Min-Ying Su4, Ning Lang5. 1. Department of Radiology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, People's Republic of China. 2. Department of Nuclear Medicine, Peking University Third Hospital, Beijing, People's Republic of China. 3. Department of Radiological Sciences, Center for Functional Onco-Imaging, University of California, 164 Irvine Hall, Irvine, CA, 92697-5020, USA. 4. Department of Radiological Sciences, Center for Functional Onco-Imaging, University of California, 164 Irvine Hall, Irvine, CA, 92697-5020, USA. msu@uci.edu. 5. Department of Radiology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, People's Republic of China. langning800129@126.com.
Abstract
PURPOSE: To investigate the correlation of parameters measured by dynamic-contrast-enhanced MRI (DCE-MRI) and 18F-FDG PET/CT in spinal tumors, and their role in differential diagnosis. METHODS: A total of 49 patients with pathologically confirmed spinal tumors, including 38 malignant, six benign and five borderline tumors, were analyzed. The MRI and PET/CT were done within 3 days, before biopsy. On MRI, the ROI was manually placed on area showing the strongest enhancement to measure pharmacokinetic parameters Ktrans and kep. On PET, the maximum standardized uptake value SUVmax was measured. The parameters in different histological groups were compared. ROC was performed to differentiate between the two largest subtypes, metastases and plasmacytomas. Spearman rank correlation was performed to compare DCE-MRI and PET/CT parameters. RESULTS: The Ktrans, kep and SUVmax were not statistically different among malignant, benign and borderline groups (P = 0.95, 0.50, 0.11). There was no significant correlation between Ktrans and SUVmax (r = - 0.20, P = 0.18), or between kep and SUVmax (r = - 0.16, P = 0.28). The kep was significantly higher in plasmacytoma than in metastasis (0.78 ± 0.17 vs. 0.61 ± 0.18, P = 0.02); in contrast, the SUVmax was significantly lower in plasmacytoma than in metastasis (5.58 ± 2.16 vs. 9.37 ± 4.26, P = 0.03). In differential diagnosis, the AUC of kep and SUVmax was 0.79 and 0.78, respectively. CONCLUSIONS: The vascular parameters measured by DCE-MRI and glucose metabolism measured by PET/CT from the most aggressive tumor area did not show a significant correlation. The results suggest they provide complementary information reflecting different aspects of the tumor, which may aid in diagnosis of spinal lesions. These slides can be retrieved under Electronic Supplementary Material.
PURPOSE: To investigate the correlation of parameters measured by dynamic-contrast-enhanced MRI (DCE-MRI) and 18F-FDG PET/CT in spinal tumors, and their role in differential diagnosis. METHODS: A total of 49 patients with pathologically confirmed spinal tumors, including 38 malignant, six benign and five borderline tumors, were analyzed. The MRI and PET/CT were done within 3 days, before biopsy. On MRI, the ROI was manually placed on area showing the strongest enhancement to measure pharmacokinetic parameters Ktrans and kep. On PET, the maximum standardized uptake value SUVmax was measured. The parameters in different histological groups were compared. ROC was performed to differentiate between the two largest subtypes, metastases and plasmacytomas. Spearman rank correlation was performed to compare DCE-MRI and PET/CT parameters. RESULTS: The Ktrans, kep and SUVmax were not statistically different among malignant, benign and borderline groups (P = 0.95, 0.50, 0.11). There was no significant correlation between Ktrans and SUVmax (r = - 0.20, P = 0.18), or between kep and SUVmax (r = - 0.16, P = 0.28). The kep was significantly higher in plasmacytoma than in metastasis (0.78 ± 0.17 vs. 0.61 ± 0.18, P = 0.02); in contrast, the SUVmax was significantly lower in plasmacytoma than in metastasis (5.58 ± 2.16 vs. 9.37 ± 4.26, P = 0.03). In differential diagnosis, the AUC of kep and SUVmax was 0.79 and 0.78, respectively. CONCLUSIONS: The vascular parameters measured by DCE-MRI and glucose metabolism measured by PET/CT from the most aggressive tumor area did not show a significant correlation. The results suggest they provide complementary information reflecting different aspects of the tumor, which may aid in diagnosis of spinal lesions. These slides can be retrieved under Electronic Supplementary Material.
Entities:
Keywords:
Magnetic resonance imaging; Positron emission tomography/computed tomography; Spinal neoplasms
Authors: Atin Saha; Kyung K Peck; Eric Lis; Andrei I Holodny; Yoshiya Yamada; Sasan Karimi Journal: Spine (Phila Pa 1976) Date: 2014-11-15 Impact factor: 3.468
Authors: Sang Ho Lee; Andreas Rimner; Emily Gelb; Joseph O Deasy; Margie A Hunt; John L Humm; Neelam Tyagi Journal: Int J Radiat Oncol Biol Phys Date: 2018-03-02 Impact factor: 7.038
Authors: N R Khadem; S Karimi; K K Peck; Y Yamada; E Lis; J Lyo; M Bilsky; H A Vargas; A I Holodny Journal: AJNR Am J Neuroradiol Date: 2012-05-03 Impact factor: 3.825
Authors: Theresia Sarabhai; Alexander Tschischka; Vanessa Stebner; Felix Nensa; Axel Wetter; Rainer Kimmig; Michael Forsting; Ken Herrmann; Lale Umutlu; Johannes Grueneisen Journal: Clin Imaging Date: 2018-03-13 Impact factor: 1.605
Authors: Kee H Wong; Rafal Panek; Alex Dunlop; Dualta Mcquaid; Angela Riddell; Liam C Welsh; Iain Murray; Dow-Mu Koh; Martin O Leach; Shreerang A Bhide; Christopher M Nutting; Wim J Oyen; Kevin J Harrington; Kate L Newbold Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-21 Impact factor: 9.236
Authors: Claudia Calcagno; Sarayu Ramachandran; David Izquierdo-Garcia; Venkatesh Mani; Antoine Millon; David Rosenbaum; Ahmed Tawakol; Mark Woodward; Jan Bucerius; Erin Moshier; James Godbold; David Kallend; Michael E Farkouh; Valentin Fuster; James H F Rudd; Zahi A Fayad Journal: Eur J Nucl Med Mol Imaging Date: 2013-08-14 Impact factor: 9.236